Sophie Schmitz, Managing Partner of Partners4Access, the specialists in orphan drug access, is presenting at the 8th annual meeting of the World Orphan Drug Congress in Barcelona on November 15, 2017 on Gene Therapy.
Schmitz will be reviewing the potential of Gene Therapy to revolutionise the healthcare industry, highlighting recent successes and discussing key challenges. “Gene therapy is an area of extremes. Extreme hope of disease cure from patient groups, extreme fears from payers in light of affordability and extreme misunderstanding from others in terms of its potential and scope.”
Schmitz added, “At Partners4Access we believe in fair access across rare diseases. I anticipate gene therapy will be an important part of the future to effectively treat rare diseases. Moreover, we as a company, have an important role to play in helping stakeholders get gene therapy access right.’’
P4A will be joined on the podium by Catapult Gene and Cell Therapy’s Panos Kefalas. Focussing on reimbursement considerations for gene therapy, Kefalas will share his insights on the key area that manufacturers can address to make a positive commercial impact.
The event, Gene Therapy at a crossroad: Evolution or Revolution? will be held between 13:40-14:10 on November 15.
For more information, please go to https://partners4access.com/events/ and www.terrapinn.com/conference/world-orphan-drug-congress/index.stm
Partners4Access are global consultants specialised in orphan drug access. The company support the biotechnology and pharmaceutical industry along their launch journey to help secure successful price, reimbursement and access for orphan drugs. Partners4Access has solid partnerships with clients supporting their strategy and operations to effectively ensure launch success.
For more information e-mail email@example.com, see our website www.partners4access.com or call us on +44(0)20 38743300